245 related articles for article (PubMed ID: 24196163)
1. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
[TBL] [Abstract][Full Text] [Related]
2. Modulating native GABA
Kallay L; Keskin H; Ross A; Rupji M; Moody OA; Wang X; Li G; Ahmed T; Rashid F; Stephen MR; Cottrill KA; Nuckols TA; Xu M; Martinson DE; Tranghese F; Pei Y; Cook JM; Kowalski J; Taylor MD; Jenkins A; Pomeranz Krummel DA; Sengupta S
J Neurooncol; 2019 May; 142(3):411-422. PubMed ID: 30725256
[TBL] [Abstract][Full Text] [Related]
3. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
4. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
5. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
7.
Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
[TBL] [Abstract][Full Text] [Related]
8. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.
Li Y; Guessous F; Johnson EB; Eberhart CG; Li XN; Shu Q; Fan S; Lal B; Laterra J; Schiff D; Abounader R
Lab Invest; 2008 Feb; 88(2):98-111. PubMed ID: 18059365
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
10. A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors.
Staal JA; Pei Y; Rood BR
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775567
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
12. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.
Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA
Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907
[TBL] [Abstract][Full Text] [Related]
13. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.
Weeraratne SD; Amani V; Neiss A; Teider N; Scott DK; Pomeroy SL; Cho YJ
Neuro Oncol; 2011 Feb; 13(2):165-75. PubMed ID: 21177782
[TBL] [Abstract][Full Text] [Related]
14. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.
Weeraratne SD; Amani V; Teider N; Pierre-Francois J; Winter D; Kye MJ; Sengupta S; Archer T; Remke M; Bai AH; Warren P; Pfister SM; Steen JA; Pomeroy SL; Cho YJ
Acta Neuropathol; 2012 Apr; 123(4):539-52. PubMed ID: 22402744
[TBL] [Abstract][Full Text] [Related]
16. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
17. Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma.
Zomerman WW; Plasschaert SLA; Conroy S; Scherpen FJ; Meeuwsen-de Boer TGJ; Lourens HJ; Guerrero Llobet S; Smit MJ; Slagter-Menkema L; Seitz A; Gidding CEM; Hulleman E; Wesseling P; Meijer L; van Kempen LC; van den Berg A; Warmerdam DO; Kruyt FAE; Foijer F; van Vugt MATM; den Dunnen WFA; Hoving EW; Guryev V; de Bont ESJM; Bruggeman SWM
Cell Rep; 2018 Mar; 22(12):3206-3216. PubMed ID: 29562177
[TBL] [Abstract][Full Text] [Related]
18. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
20. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]